ATR inhibitors NU6027 and VE-821 have been shown to increase the cytotoxic activity of PARP inhibitors (rucaparib and veliparib) in two BRCA wild-type cancer cell lines and various ovarian cancer cell lines [35,107]. Here, ATR is linked to ovarian carcinoma.